1,25-Dihydroxyvitamin D3 and extracellular calcium promote mineral deposition via NPP1 activity in a mature osteoblast cell line MLO-A5

Molecular and Cellular Endocrinology

Volumn 412, Issue , 2015, Pages 140-147

  Yang, Dongqing ^a   Turner, Andrew G ^a,b   Wijenayaka, Asiri R ^a   Anderson, Paul H ^a,b   Morris, Howard A ^a,b,c   Atkins, Gerald J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c Endocrine Bone Research Laboratory   (Australia)

Author keywords

1,25 Dihydroxyvitamin D; Alkaline phosphatase; Enpp1; Inorganic phosphate; Osteoblast differentiation; Pyrophosphate

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; COLECALCIFEROL 24 HYDROXYLASE; COLLAGEN TYPE 1; CONNEXIN 43; DENTIN MATRIX PROTEIN 1; MESSENGER RNA; NUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; OSTEOCALCIN; PHOSPHATE REGULATING ENDOPEPTIDASE HOMOLOG X LINKED; PHOSPHODIESTERASE; PROTEINASE; PYROPHOSPHATE; TISSUE NON SPECIFIC ALKALINE PHOSPHATASE; TYPE I COLLAGEN ALPHA CHAIN 1; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; CALCIUM; DIHYDROXY-VITAMIN D3; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; INORGANIC PYROPHOSPHATASE; VITAMIN D;

ANIMAL CELL; ARTICLE; BONE MINERALIZATION; CELL DIFFERENTIATION; CONTROLLED STUDY; EXTRACELLULAR CALCIUM; GENE EXPRESSION; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; GENETICS; METABOLISM;

ANIMALS; CALCIFICATION, PHYSIOLOGIC; CALCIUM; CELL DIFFERENTIATION; CELL LINE; GENE EXPRESSION; MICE; OSTEOBLASTS; OSTEOCALCIN; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 84934989639     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.06.005     Document Type: Article

References (42)

1. Addison W.N., Azari F., Sorensen E.S., Kaartinen M.T., McKee M.D. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J. Biol. Chem 2007, 282:15872-15883.
2. Anderson H.C., Harmey D., Camacho N.P., Garimella R., Sipe J.B., Tague S., et al. Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. Am. J. Pathol 2005, 166:1711-1720.
3. Anderson P.H., O'Loughlin P.D., May B.K., Morris H.A. Modulation of CYP27B1 and CYP24 mRNA expression in bone is independent of circulating 1,25(OH)2D3 levels. Bone 2005, 36:654-662.
4. Anderson P.H., Sawyer R.K., Moore A.J., May B.K., O'Loughlin P.D., Morris H.A. Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model. J. Bone Miner. Res 2008, 23:1789-1797.
5. Atkins G.J., Kostakis P., Pan B., Farrugia A., Gronthos S., Evdokiou A., et al. RANKL expression is related to the differentiation state of human osteoblasts. J. Bone Miner. Res 2003, 18:1088-1098.
6. Atkins G.J., Anderson P.H., Findlay D.M., Welldon K.J., Vincent C., Zannettino A.C., et al. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone 2007, 40:1517-1528.
7. Atkins G.J., Rowe P.S., Lim H.P., Welldon K.J., Ormsby R., Wijenayaka A.R., et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J. Bone Miner. Res 2011, 26:1425-1436.
8. Avenell A., Mak J.C., O'Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst. Rev 2014, (4). CD000227.
9. Barragan-Adjemian C., Nicolella D., Dusevich V., Dallas M.R., Eick J.D., Bonewald L.F. Mechanism by which MLO-A5 late osteoblasts/early osteocytes mineralize in culture: similarities with mineralization of lamellar bone. Calcif. Tissue Int 2006, 79:340-353.
10. Batra N., Kar R., Jiang J.X. Gap junctions and hemichannels in signal transmission, function and development of bone. Biochim. Biophys. Acta 2012, 1818:1909-1918.
11. Bischoff-Ferrari H.A., Dietrich T., Orav E.J., Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am. J. Med 2004, 116:634-639.
12. Bischoff-Ferrari H.A., Willett W.C., Orav E.J., Lips P., Meunier P.J., Lyons R.A., et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N. Engl. J. Med 2012, 367:40-49.
13. Caudarella R., Vescini F., Buffa A., Rizzoli E., Ceccoli L., Francucci C.M. Role of calcium-sensing receptor in bone biology. J. Endocrinol. Invest 2011, 34:13-17.
14. Chen Y.C., Ninomiya T., Hosoya A., Hiraga T., Miyazawa H., Nakamura H. 1alpha,25-Dihydroxyvitamin D3 inhibits osteoblastic differentiation of mouse periodontal fibroblasts. Arch. Oral Biol 2012, 57:453-459.
15. Ducy P. Cbfa1: a molecular switch in osteoblast biology. Dev. Dyn 2000, 219:461-471.
16. Gregory C.A., Gunn W.G., Peister A., Prockop D.J. An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal. Biochem 2004, 329:77-84.
17. Grobben B., Claes P., Roymans D., Esmans E.L., Van Onckelen H., Slegers H. Ecto-nucleotide pyrophosphatase modulates the purinoceptor-mediated signal transduction and is inhibited by purinoceptor antagonists. Br. J. Pharmacol 2000, 130:139-145.
18. Harmey D., Hessle L., Narisawa S., Johnson K.A., Terkeltaub R., Millan J.L. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am. J. Pathol 2004, 164:1199-1209.
19. Ho A.M., Johnson M.D., Kingsley D.M. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000, 289:265-270.
20. Kato Y., Boskey A., Spevak L., Dallas M., Hori M., Bonewald L.F. Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture. J. Bone Miner. Res 2001, 16:1622-1633.
21. Khanna-Jain R., Vuorinen A., Sandor G.K., Suuronen R., Miettinen S. Vitamin D(3) metabolites induce osteogenic differentiation in human dental pulp and human dental follicle cells. J. Steroid Biochem. Mol. Biol 2010, 122:133-141.
22. Kim S., Shevde N.K., Pike J.W. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts. J. Bone Miner. Res 2005, 20:305-317.
23. Kumarasinghe D.D., Sullivan T., Kuliwaba J.S., Fazzalari N.L., Atkins G.J. Evidence for the dysregulated expression of TWIST1, TGFbeta1 and SMAD3 in differentiating osteoblasts from primary hip osteoarthritis patients. Osteoarthritis Cartilage 2012, 20:1357-1366.
24. Lambrecht G., Friebe T., Grimm U., Windscheif U., Bungardt E., Hildebrandt C., et al. PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur. J. Pharmacol 1992, 217:217-219.
25. Larsson L., Ohman S. Serum ionized calcium and corrected total calcium in borderline hyperparathyroidism. Clin. Chem 1978, 24:1962-1965.
26. Lieben L., Masuyama R., Torrekens S., Van Looveren R., Schrooten J., Baatsen P., et al. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J. Clin. Invest 2012, 122:1803-1815.
27. Lyons A.B., Parish C.R. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 1994, 171:131-137.
28. Mackenzie N.C., Huesa C., Rutsch F., MacRae V.E. New insights into NPP1 function: lessons from clinical and animal studies. Bone 2012, 51:961-968.
29. Martin A., David V., Laurence J.S., Schwarz P.M., Lafer E.M., Hedge A.M., et al. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 2008, 149:1757-1772.
30. Matsumoto T., Igarashi C., Takeuchi Y., Harada S., Kikuchi T., Yamato H., et al. Stimulation by 1,25-dihydroxyvitamin D3 of in vitro mineralization induced by osteoblast-like MC3T3-E1 cells. Bone 1991, 12:27-32.
31. Nam H.K., Liu J., Li Y., Kragor A., Hatch N.E. Ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) protein regulates osteoblast differentiation. J. Biol. Chem 2011, 286:39059-39071.
32. Owen T.A., Aronow M.S., Barone L.M., Bettencourt B., Stein G.S., Lian J.B. Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in normal rat osteoblast cultures. Endocrinology 1991, 128:1496-1504.
33. Prideaux M., Loveridge N., Pitsillides A.A., Farquharson C. Extracellular matrix mineralization promotes E11/gp38 glycoprotein expression and drives osteocytic differentiation. PLoS ONE 2012, 7:e36786.
34. Reid I.R., Bolland M.J., Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 2014, 383:146-155.
35. Terkeltaub R. Physiologic and pathologic functions of the NPP nucleotide pyrophosphatase/phosphodiesterase family focusing on NPP1 in calcification. Purinergic Signal 2006, 2:371-377.
36. Vincent C., Findlay D.M., Welldon K.J., Wijenayaka A.R., Zheng T.S., Haynes D.R., et al. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J. Bone Miner. Res 2009, 24:1434-1449.
37. Welldon K.J., Findlay D.M., Evdokiou A., Ormsby R.T., Atkins G.J. Calcium induces pro-anabolic effects on human primary osteoblasts associated with acquisition of mature osteocyte markers. Mol. Cell. Endocrinol 2013, 376:85-92.
38. Woeckel V.J., Alves R.D., Swagemakers S.M., Eijken M., Chiba H., van der Eerden B.C., et al. 1Alpha,25-(OH)2D3 acts in the early phase of osteoblast differentiation to enhance mineralization via accelerated production of mature matrix vesicles. J. Cell. Physiol 2010, 225:593-600.
39. Yamaguchi M., Weitzmann M.N. High dose 1,25(OH)2D3 inhibits osteoblast mineralization in vitro. Int. J. Mol. Med 2012, 29:934-938.
40. Yamamoto Y., Yoshizawa T., Fukuda T., Shirode-Fukuda Y., Yu T., Sekine K., et al. Vitamin D receptor in osteoblasts is a negative regulator of bone mass control. Endocrinology 2013, 154:1008-1020.
41. Yang D., Atkins G.J., Turner A.G., Anderson P.H., Morris H.A. Differential effects of 1,25-dihydroxyvitamin D on mineralisation and differentiation in two different types of osteoblast-like cultures. J. Steroid Biochem. Mol. Biol 2013, 136:166-170.
42. Yellowley C.E., Li Z., Zhou Z., Jacobs C.R., Donahue H.J. Functional gap junctions between osteocytic and osteoblastic cells. J. Bone Miner. Res 2000, 15:209-217.